

Equity | Australia | Packaging  
30 January 2012

# 1H result in the bag

## 1H result comes in above expectations

CKL reported a normalised 1H12 NPAT of A\$4.7m, up 26% on the pcg and A\$0.7m higher than our estimates. Growth was driven by contributions from recent acquisitions, new product lines (paper cups) and reasonable growth in the legacy business. This is a good result given the current macro backdrop. The reported NPAT was down 179% or \$5m due to the one-off \$9.9m incurred in integrating the recently acquired CHH business. Retain Buy.

## New products, acquisitions and synergies to drive FY12

We expect FY12 normalised NPAT to increase by 15%, driven mainly by the full year contribution from CHH, increased sales from new products and moderate growth in legacy businesses. Management is confident on driving cost synergies by integrating the CHH business with CKL's folding carton business. In addition, CKL also plans to drive revenue growth from the new paper cup division.

## Scope for more organic growth beyond FY12

The acquisition of CHH and the new paper cup line has given CKL access to new customers and product lines especially in the food segment. We believe CKL is now ideally positioned to cross sell other product offerings and drive organic sales growth beyond FY12/13. Given the enhanced product offering CKL is already seeing an increase in the number of major customers re-signing contracts.

## Buy retained - Stable operation with growth opportunities

Backed by a strong management team, with a solid track record of sales growth, operational excellence and value accretive acquisitions, we expect CKL to generate synergies at CHH and stable growth in the legacy business over the next few years. We upgrade our FY12 EPS forecasts by 11% and FY13 by 10%. Trading below its fundamental value (DCF of \$0.91ps), we think CKL remains a good defensive, high-yield play with good cash flows post the CHH integration.

## Estimates (Jun)

(A\$)	2010A	2011A	2012E	2013E	2014E
Net Profit b/f Abnormals	6	7	8	9	9
EPS	0.079	0.087	0.100	0.105	0.116
EPS Change (YoY)	15.5%	9.9%	14.9%	5.4%	10.4%
Dividend / Share	0.043	0.033	0.035	0.035	0.035
Free Cash Flow / Share	0.095	(0.101)	(0.106)	0.078	0.088

## Valuation (Jun)

	2010A	2011A	2012E	2013E	2014E
P/E	9.10x	8.28x	7.21x	6.84x	6.19x
Dividend Yield	5.90%	4.51%	4.86%	4.86%	4.86%
EV / EBITDA*	5.63x	6.77x	5.97x	5.61x	5.10x
Free Cash Flow Yield*	13.11%	-13.94%	-14.70%	10.86%	12.26%

\* For full definitions of *iQmethod*<sup>SM</sup> measures, see page 8.

## Merrill Lynch

A subsidiary of  
Bank of America Corporation

Ramanan Sooriyakumar, CFA &gt;&gt;+61 3 9659 2775

Research Analyst  
Merrill Lynch (Australia)  
ramanan.sooriyakumar@baml.com

Ben Chan, CFA &gt;&gt; +61 3 9659 2004

Research Analyst  
Merrill Lynch (Australia)  
ben.chan@baml.com

Brent Walsh &gt;&gt; +61 3 9659 2516

Research Analyst  
Merrill Lynch (Australia)  
brent.walsh@baml.com

## Stock Data

Price	A\$0.720
Price Objective	A\$0.890
Date Established	29-Dec-2010
Investment Opinion	C-1-7
Volatility Risk	HIGH
52-Week Range	A\$0.600-A\$0.770
Mrkt Val / Shares Out (mn)	US\$62 / 81.5
Market Value (mn)	A\$59
Average Daily Volume	14,320
BofAML Ticker / Exchange	XBVVF / ASX
Bloomberg / Reuters	CKL AU / CKLAX
ROE (2012E)	11.2%
Net Dbt to Eqty (Jan-2012A)	46.6%
Est. 5-Yr EPS / DPS Growth	3.2% / 11.2%
Free Float	68.0%

## Key Changes

(A\$)	Previous	Current
2012E EPS	0.09	0.10
2013E EPS	0.10	0.11
2014E EPS	0.11	0.12
2012E EBITDA (m)	18.2	19.1
2013E EBITDA (m)	19.0	19.6
2014E EBITDA (m)	19.6	20.7

>> Employed by a non-US affiliate of MLPF&S and is not registered/qualified as a research analyst under the FINRA rules.

Refer to "Other Important Disclosures" for information on certain BofA Merrill Lynch entities that take responsibility for this report in particular jurisdictions.

BofA Merrill Lynch does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 9 to 11. Analyst Certification on Page 7. Price Objective Basis/Risk on page 7. Link to Definitions on page 7. 11131152

30 January 2012

## iQprofile<sup>SM</sup> Colorpak Ltd

Key Income Statement Data (Jun)	2010A	2011A	2012E	2013E	2014E
<b>(A\$ Millions)</b>					
<b>Sales</b>	<b>80</b>	<b>127</b>	<b>201</b>	<b>206</b>	<b>213</b>
Associates & Other Revenue	1	0	2	2	2
Operating Expenses	(66)	(112)	(183)	(188)	(194)
<b>EBITDA</b>	<b>15</b>	<b>16</b>	<b>19</b>	<b>20</b>	<b>21</b>
Depreciation & Amortization	(3)	(3)	(4)	(3)	(3)
<b>EBIT</b>	<b>12</b>	<b>13</b>	<b>15</b>	<b>16</b>	<b>17</b>
Net Interest & Other income	(2)	(2)	(4)	(4)	(4)
Pretax Income	9	10	12	12	14
Tax (expense) / Benefit	(3)	(3)	(4)	(4)	(4)
Outside Equity interest in Npat	0	0	0	0	0
Preference dividends	NA	NA	NA	NA	NA
<b>Net Profit b/f Abnormals</b>	<b>6</b>	<b>7</b>	<b>8</b>	<b>9</b>	<b>9</b>
Non-Recurring Items	0	9	(7)	0	0
Net Income (Reported)	6	16	1	9	9

### Key Cash Flow Statement Data

EBITDA	15	16	19	20	21
Change in Working Capital	(2)	(8)	(2)	(2)	(2)
Other C'flow Items before int & tax	0	0	0	0	0
Net Interest Paid	(2)	(3)	(4)	(4)	(4)
Tax Paid	(1)	(3)	(3)	(4)	(4)
Other C'flow from Operations	0	0	(10)	0	0
<b>Cash Flow from Operations</b>	<b>9</b>	<b>3</b>	<b>1</b>	<b>10</b>	<b>11</b>
Capital Expenditure (PP&E)	(1)	(11)	(10)	(4)	(4)
(Acquisition) / Disposal of Investments	0	0	0	0	0
Other C'flow from Investing	0	0	1	0	0
<b>Cash Flow from Investing</b>	<b>(1)</b>	<b>(11)</b>	<b>(9)</b>	<b>(4)</b>	<b>(4)</b>
Shares Issue / (Repurchase)	0	0	0	0	0
Dividend paid	(3)	(3)	(3)	(3)	(3)
Other C'flow from Financing	(5)	8	13	(2)	(2)
<b>Cash Flow from Financing</b>	<b>(7)</b>	<b>5</b>	<b>10</b>	<b>(4)</b>	<b>(4)</b>
<b>Free Cash Flow</b>	<b>8</b>	<b>(8)</b>	<b>(9)</b>	<b>6</b>	<b>7</b>
<b>Net Debt</b>	<b>23</b>	<b>34</b>	<b>45</b>	<b>41</b>	<b>37</b>

### Key Balance Sheet Data

Cash Equivalents	0	0	0	2	5
Receivables & Inventories	23	69	67	69	71
Property, Plant & Equipment	28	41	42	42	42
Intangibles	46	46	46	46	46
Other assets	1	6	6	6	6
<b>Total Assets</b>	<b>97</b>	<b>161</b>	<b>161</b>	<b>165</b>	<b>171</b>
Payables	9	25	20	20	20
Provisions	3	26	24	24	24
Short term debt & Long term debt	23	34	45	44	42
Other Liabilities	3	2	1	1	1
<b>Total Liabilities</b>	<b>37</b>	<b>88</b>	<b>90</b>	<b>88</b>	<b>87</b>
<b>Total Equity</b>	<b>60</b>	<b>73</b>	<b>72</b>	<b>77</b>	<b>84</b>

### iQmethod<sup>SM</sup> - Bus Performance\*

Return on Capital Employed	9.4%	8.4%	8.6%	8.8%	9.1%
Return on Equity	11.0%	10.6%	11.2%	11.5%	11.8%
Operating Margin	14.5%	10.0%	7.7%	7.9%	8.2%
EBITDA Margin	18.0%	12.4%	9.4%	9.5%	9.7%

### iQmethod<sup>SM</sup> - Quality of Earnings\*

Cash Realization Ratio	1.4x	0.4x	0.1x	1.2x	1.2x
Dividend Payout Ratio	53.7%	37.4%	35.0%	33.2%	30.1%
Tax Rate (Reported)	29.9%	30.9%	30.2%	30.3%	30.3%
Net Debt-to-Equity Ratio	37.6%	46.6%	62.3%	53.2%	43.8%
Interest Cover	4.7x	5.1x	4.1x	4.1x	4.5x

### Key Metrics

Franking	100%	100%	100%	100%	100%
----------	------	------	------	------	------

\* For full definitions of iQmethod<sup>SM</sup> measures, see page 8.

### Company Description

Colorpak is a major participant in the A\$600m folding-carton segment of Australia's paper and board packaging industry. The company's products are heavily exposed to the higher margin pharmaceuticals and healthcare industries. The company is based in Melbourne, Australia.

### Investment Thesis

Backed by a strong management team, which has a solid track record of sales growth and also own a significant proportion of stock, CKL should enjoy solid sales and earnings growth driven by underlying growth in key markets, continued market share gains and highly accretive acquisitions.

### Stock Data

Price to Book Value 0.8x

## Buy retained post strong 1H result

CKL reported a normalised 1H12 NPAT of A\$4.7m, up 26% on the pcp and A\$0.7m higher than our estimates. Growth was driven by contributions from recent acquisitions, new product lines (paper cups) and stable volumes in the legacy business. This is a good result given the current macro backdrop. The reported NPAT was down 179% or \$5m due to the one-off \$9.9m incurred in integrating the recently acquired CHH business. Retain Buy.

**New products, acquisitions and synergies to drive FY12.** We expect FY12 normalised NPAT to increase by 15%, driven by full year contribution from CHH, cost synergies, increased sales from new products and moderate growth in legacy businesses. Management is confident on driving synergies by integrating the CHH business with CKL's folding carton business. In addition, CKL also plans to drive revenue growth from the new paper cup division.

**Buy retained – Stable operation with new growth opportunities.** Backed by a strong management team, with a solid track record of sales growth, operational excellence and value accretive acquisitions, we expect CKL to generate synergies in the CHH business and stable growth in the legacy business over the next few years. We upgrade FY12 EPS by 11% and FY13 by 10%. Trading below its fundamental value (DCF of \$0.91ps), we think CKL remains a good defensive, high-yield play with good cash flows (post the integration).

## 1H12 Result at a glance

Below we summarise the key financial highlights from CKL's result:

Table 1: 1H12 result at glance

	1H11	1H12	Chg %
Sales Revenue	43.5	104.1	139.4%
EBITDA	8.0	10.5	31.9%
D&A	-1.4	-2.0	39.7%
EBIT	6.6	8.6	30.2%
Net Interest	-1.1	-1.7	52.6%
EBT	5.4	6.8	25.5%
Tax Expense	-1.6	-2.1	25.6%
NPAT	3.8	4.7	25.5%
EBITDA Margin	18.4%	10.1%	-824bps
EBIT Margin	15.1%	8.2%	-689bps
EPS (A\$ cents)	4.66	5.83	24.9%
DPS (A\$ cents)	1.50	1.50	0.0%

Source:CKL, Merrill Lynch Global Research


- **NPAT:** CKL reported a net normalised profit of A\$4.7m, up 25.5% on the pcp and A\$0.7m higher than our estimates. The result was driven by contributions from the CHH business and the new paper cup division.
- **Margins.** EBITDA margins fell sharply to 9.9% in 1H12 from 18.2% in 1H11, driven mainly by the lower margins at the acquired CHH business.
- **Revenue drivers:** Sales rose 139% on the pcp mainly due to the CHH contribution. The legacy business has continued to track well despite the macro conditions.
- **Cost drivers:** While sales increased by 139%, CKL's cost base increased by 166% in FY11. This was mainly due to a 157% increase in raw material costs and 214% increase in occupancy costs (including CHH).
- **Cash flow:** FCF (excluding CHH acquisition) came at negative \$8m mainly due to business combination and restructuring costs.
- **Gearing (D/D+E):** Net debt increased by \$9.4m to \$44m, mainly to finance the CHH acquisition and the related integration costs.
- **Financial position:** CKL remains within its banks covenants with annualised net debt/EBITDA of 2.1x vs. 2.2x in FY11 (vs. covenant of ~3.0x).
- **Final dividend:** CKL declared an interim dividend of 1.50cps and the record date is 2 Mar 2012.
- **Outlook:** The focus for the remainder of the year will remain on integrating the CHH business, while the underlying legacy business continues to grow.

## Key Highlights

### Legacy business stable, new products to drive growth


Despite the tough macro economic conditions, increasing competition from globalisation and customers looking to move volumes abroad it was encouraging to see the legacy business tracking well in 1H. We believe CKL, through the acquisition of CHH and introducing new product lines, will be able to win more customers in the legacy business. CKL's overall sales grew by 139% in 1H12 driven mainly by contribution from the CHH acquisition.

Chart 1: Sales rose 139% in 1H12 vs. the pcp due to acquisitions



Source: Company reports, Merrill Lynch Global Research

Chart 2: CKL's sales exposure by segment – 1H12




Source: Company reports, Merrill Lynch Global Research

### 1H12 EBITDA margins contract on CHH, but up sequentially


EBITDA fell from 18.2% in 1H11 to 9.9% in 1H12, mainly due low EBITDA margins from the CHH operations. RM costs were also higher, increasing by 146%, while sales increased by 121%. That said EBITDA margins are higher than the 2H11 which could be due to the seasonality as well as CKL generating synergies in the acquired operations. We expect EBITDA to increase to \$19.1m in FY12 (vs. \$15.8m in FY11), and margins to decline to 9.5% from 12.4% in FY11.

Chart 3: EBITDA margin fell from 18.2% in 1H11 to 9.9% in 1H12 mainly due to CHH and higher RM costs.



Source: CKL, Merrill Lynch Global Research estimates

Chart 4: Revenue vs. RM costs – RM costs outpaced the growth in overall sales (which we believe is mainly due to CHH)




Source: CKL, Merrill Lynch Global Research estimates

▪ **Higher gearing but well within debt covenants**


**CKL's net debt increased to \$44m vs. \$22m in the pcp mainly due to capex of \$5.6m and CHH acquisition cost of \$5m.** Most of the capex was spent on the new plastic cups division. While this has increased CKL's gearing to 39% from 27% in 1H11, the net debt to EBITDA ratio remains at a comfortable 2.1x (we estimate the gearing covenants to be around ~3x). Given the contribution from the new businesses we expect net debt ratios to start improving from 1H13.

**Chart 5: CKL's gearing ratio have risen sharply due to the CHH acquisition**



Source: CKL, Merrill Lynch Global Research estimates

**Chart 6: Capex (excl business purchases) increased as CKL invested in plastic cups. This also led to higher debt levels for CKL**



Source: CKL, Merrill Lynch Global Research estimates

**Table 2: CKL DCF valuation**

PV of CFs	A\$m	11.2
PV of terminal value	A\$m	93.2
Enterprise Value	A\$m	104.4
Net Debt	A\$m	43.6
<b>Equity Value</b>	<b>A\$m</b>	<b>60.9</b>
Fully diluted ordinary shares	Million	81.2
<b>Equity Value per share</b>	<b>A\$ps</b>	<b>0.75</b>
Franking credits	A\$ps	0.14
<b>DCF</b>	<b>A\$ps</b>	<b>0.89</b>

Source: Merrill Lynch Global Research estimates

**Table 3: CKL PER valuation**

	FY11A	FY12E	FY13E
Through-the-cycle PER Multiple	10.0x	10.0x	10.0x
EPS Pre-Goodwill (diluted)	8.7	10.0	10.5
<b>Value per ordinary share</b>	<b>\$0.87</b>	<b>\$1.00</b>	<b>\$1.05</b>

Source: Merrill Lynch Global Research estimates

## Outlook

▪ **Leveraging on recent acquisitions and capacity additions**

With the legacy business continuing to track well, we expect new contribution from CHH and plastic cups division to drive growth in FY12. Beyond FY12, we believe these new businesses will complement the existing legacy business and help CKL secure new orders by leveraging its expanded product offerings. CKL is also planning to market some of the existing products to the new customer base acquired via the CHH acquisition.

## Valuation summary

### DCF valuation

Our DCF for CKL is \$0.89ps and is based on a WACC of 10.5% and a terminal growth rate of 2.5%. Whilst we consider the DCF valuation to be the most appropriate methodology to value this company, we recognise that the stock also looks attractive on different metrics such as PER.

### PER valuation

We apply a mid-cycle multiple for the stock of 10x, which is a 20% discount to the all industrials ex financials of 12.1x. In our view such discount is reasonable, given CKL's inherent liquidity/size issues and the cyclical industry it operates in.

Applying this 10x multiple to FY12 EPS of 10cps, we derive a PER based valuation for the stock of A\$1.00ps, a 40% premium to the current share price. Importantly, were the stock to reach our price target of A\$0.89ps in 12 months time, CKL would be trading on a FY12 PER of 8.9x, which we do not view as demanding.

## Financials

Table 4: Statement of Financial Performance

Year ending June (A\$m)	2010A	2011A	2012E	2013E	2014E
Trading revenue	80.2	127.4	200.7	206.0	211.1
- change	3.0%	58.9%	57.6%	2.7%	2.5%
<b>EBITDA</b>	<b>14.6</b>	<b>15.8</b>	<b>19.1</b>	<b>19.7</b>	<b>20.3</b>
- change	8.6%	8.5%	20.6%	3.3%	2.9%
Depreciation	-3.0	-3.1	-3.7	-3.4	-3.4
Amortisation	0.0	0.0	0.0	0.0	0.0
<b>EBIT</b>	<b>11.6</b>	<b>12.7</b>	<b>15.4</b>	<b>16.3</b>	<b>16.9</b>
- change	11.4%	9.5%	21.3%	6.0%	3.5%
Net interest	-2.5	-2.5	-3.7	-4.0	-3.8
<b>EBT</b>	<b>9.1</b>	<b>10.2</b>	<b>11.7</b>	<b>12.4</b>	<b>13.1</b>
Tax expense	-2.7	-3.2	-3.5	-3.7	-4.0
<b>NPAT att. to s/hers</b>	<b>6.4</b>	<b>7.1</b>	<b>8.1</b>	<b>8.6</b>	<b>9.1</b>
- change	15.5%	10.1%	15.4%	5.8%	6.1%
Net significant items	0.0	8.8	-7.0	0.0	0.0
<b>Reported NPAT</b>	<b>6.4</b>	<b>15.9</b>	<b>1.2</b>	<b>8.6</b>	<b>9.1</b>
Norm EPS	7.9	8.7	10.0	10.6	5.2
EPS change	15.5%	9.9%	14.9%	5.8%	0.0%
<b>PER</b>	<b>9.0</b>	<b>8.2</b>	<b>7.1</b>	<b>6.7</b>	<b>13.6</b>

Source:CKL, Merrill Lynch Global Research estimates

Table 5: Ratios

Year ending June (A\$m)	2010A	2011A	2012E	2013E	2014E
<b>Profitability Ratios</b>					
EBIT margin	14.5%	10.0%	7.7%	7.9%	8.0%
NPAT margin	8.0%	5.5%	4.1%	4.2%	4.3%
Effective tax rate	29.9%	30.9%	30.2%	30.3%	30.3%
NOPLAT pre goodwill	8.1	8.8	10.7	11.4	11.8
Invested Capital	90.4	114.7	123.9	128.1	132.9
<b>ROIC (after tax)</b>	<b>9.0%</b>	<b>7.7%</b>	<b>8.7%</b>	<b>8.9%</b>	<b>8.9%</b>
ROCE	9.4%	8.4%	8.6%	8.8%	8.8%
ROA	11.9%	9.8%	9.6%	10.0%	10.1%
<b>Gearing / Cashflow Ratios</b>					
Debt / Equity	38%	47%	63%	56%	50%
Debt / Debt+Equity	27%	32%	39%	36%	33%
Debt / EBITDA	1.6x	2.2x	2.4x	2.2x	2.1x
EBITDA / Interest	5.9x	6.4x	5.1x	4.9x	5.2x
EBIT / Interest	4.7x	5.1x	4.1x	4.1x	4.4x
Gearing (ND/ND+E)	27.31%	32%	38%	35%	31%
<b>Multiples</b>					
EV/EBITDA	5.5x	5.7x	5.3x	5.0x	4.6x
EV/EBIT	6.8x	7.2x	6.6x	6.0x	5.6x

Source:CKL, Merrill Lynch Global Research estimates

## Price objective basis & risk

### Colorpak Ltd (XBVVF)

Our PO is slightly below our DCF valuation of \$0.91ps, which is based on a WACC of 10.5% and a terminal growth rate of 2.5%. Whilst we consider the DCF valuation to be the most appropriate methodology to value this company, we recognise that the stock also looks attractive on different metrics such as PER.

We apply a mid-cycle multiple for the stock of 10x, which is a 20% discount to the all industrials ex financials of 12.1x. In our view such discount is reasonable, given the inherent liquidity/size issues and the cyclical industry it operates in. Applying this 10x multiple to FY12 EPS of 10cps, we derive a valuation for the stock of A\$1.00ps, a 40% premium to the current share price. Importantly, were the stock to reach our price target of A\$0.89ps in 12 months time, CKL would be trading on a FY12 PER of 8.9x, which we do not view as demanding.

The risks to our recommendation are integration risks, product substitution, competition, contract losses, management instability and customer attrition.

## Link to Definitions

### Basic Materials

Click [here](#) for definitions of commonly used terms.

## Analyst Certification

I, Ramanan Sooriyakumar, CFA, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

### Australia - Industrials Coverage Cluster

Investment rating	Company	BofA Merrill Lynch ticker	Bloomberg symbol	Analyst
<b>BUY</b>				
	Ancor	AMCRF	AMC AU	Ben Chan, CFA
	Boart Longyear Limited	BOARF	BLY AU	Duncan Simmonds, CFA
	Colorpak Ltd	XBVVF	CKL AU	Ramanan Sooriyakumar, CFA
	Fletcher Building	YFLBF	FBU AU	Ben Chan, CFA
	Incitec Pivot Limited	ICPVF	IPL AU	Ben Chan, CFA
	James Hardie Industries	JHIUF	JHX AU	Ben Chan, CFA
	James Hardie-ADR	JHX	JHX US	Ben Chan, CFA
	Leighton Holdings Limited	LGTHF	LEI AU	Duncan Simmonds, CFA
	Nufarm Limited	NUFMF	NUF AU	Ramanan Sooriyakumar, CFA
	Onesteel	OSTLF	OST AU	Ben Chan, CFA
	Sims Metal Management	SMUPF	SGM AU	Ben Chan, CFA
<b>NEUTRAL</b>				
	Adelaide Brighton	ADBCF	ABC AU	Ben Chan, CFA
	Bluescope Steel	BLSFF	BSL AU	Ben Chan, CFA
	Campbell Brothers	CBEBF	CPB AU	Duncan Simmonds, CFA
	DuluxGroup Limited	XDLXF	DLX AU	Anna Chen, CFA
	Orica	OCLDF	ORI AU	Ben Chan, CFA
<b>UNDERPERFORM</b>				
	Boral Ltd	BOALF	BLD AU	Ben Chan, CFA
	CSR	CSRLF	CSR AU	Ben Chan, CFA

30 January 2012

**iQmethod<sup>SM</sup> Measures Definitions**

<b>Business Performance</b>	<b>Numerator</b>	<b>Denominator</b>
Return On Capital Employed	$\text{NOPAT} = (\text{EBIT} + \text{Interest Income}) * (1 - \text{Tax Rate}) + \text{Goodwill Amortization}$	Total Assets – Current Liabilities + ST Debt + Accumulated Goodwill
Return On Equity	Net Income	Shareholders' Equity
Operating Margin	Operating Profit	Sales
Earnings Growth	Expected 5-Year CAGR From Latest Actual	N/A
Free Cash Flow	Cash Flow From Operations – Total Capex	N/A
<b>Quality of Earnings</b>		
Cash Realization Ratio	Cash Flow From Operations	Net Income
Asset Replacement Ratio	Capex	Depreciation
Tax Rate	Tax Charge	Pre-Tax Income
Net Debt-To-Equity Ratio	Net Debt = Total Debt, Less Cash & Equivalents	Total Equity
Interest Cover	EBIT	Interest Expense
<b>Valuation Toolkit</b>		
Price / Earnings Ratio	Current Share Price	Diluted Earnings Per Share (Basis As Specified)
Price / Book Value	Current Share Price	Shareholders' Equity / Current Basic Shares
Dividend Yield	Annualised Declared Cash Dividend	Current Share Price
Free Cash Flow Yield	Cash Flow From Operations – Total Capex	Market Cap. = Current Share Price * Current Basic Shares
Enterprise Value / Sales	$\text{EV} = \text{Current Share Price} * \text{Current Shares} + \text{Minority Equity} + \text{Net Debt} + \text{Sales} + \text{Other LT Liabilities}$	
EV / EBITDA	Enterprise Value	Basic EBIT + Depreciation + Amortization


*iQmethod<sup>SM</sup>* is the set of BoFA Merrill Lynch standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of *iQmethod* are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.

*iQdatabase<sup>®</sup>* is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BoFA Merrill Lynch.

*iQprofile<sup>SM</sup>*, *iQmethod<sup>SM</sup>* are service marks of Merrill Lynch & Co., Inc. *iQdatabase<sup>®</sup>* is a registered service mark of Merrill Lynch & Co., Inc.

## Important Disclosures

### XBVVF Price Chart



B : Buy, N : Neutral, U : Underperform, PO : Price objective, NA : No longer valid, NR: No Rating

The Investment Opinion System is contained at the end of the report under the heading "Fundamental Equity Opinion Key". Dark grey shading indicates the security is restricted with the opinion suspended. Medium grey shading indicates the security is under review with the opinion withdrawn. Light grey shading indicates the security is not covered. Chart is current as of [December 31, 2011] or such later date as indicated.

### Investment Rating Distribution: Packaging Group (as of 01 Jan 2012)

Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	12	60.00%	Buy	9	81.82%
Neutral	6	30.00%	Neutral	5	83.33%
Sell	2	10.00%	Sell	2	100.00%

### Investment Rating Distribution: Global Group (as of 01 Jan 2012)

Coverage Universe	Count	Percent	Inv. Banking Relationships*	Count	Percent
Buy	2029	52.00%	Buy	1337	72.11%
Neutral	1009	25.86%	Neutral	657	71.34%
Sell	864	22.14%	Sell	487	60.20%

\* Companies in respect of which BofA Merrill Lynch or one of its affiliates has received compensation for investment banking services within the past 12 months. For purposes of this distribution, a stock rated Underperform is included as a Sell.

**FUNDAMENTAL EQUITY OPINION KEY:** Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. **VOLATILITY RISK RATINGS**, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. **INVESTMENT RATINGS** reflect the analyst's assessment of a stock's: (i) absolute total return potential and (ii) attractiveness for investment relative to other stocks within its *Coverage Cluster* (defined below). There are three investment ratings: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster*
Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
Underperform	N/A	≥ 20%

\* Ratings dispersions may vary from time to time where BofA Merrill Lynch Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

**INCOME RATINGS**, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. *Coverage Cluster* is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Merrill Lynch Comment referencing the stock.

Price charts for the securities referenced in this research report are available at <http://pricecharts.ml.com>, or call 1-800-MERRILL to have them mailed. In the US, retail sales and/or distribution of this report may be made only in states where these securities are exempt from registration or have been qualified for sale: ColorPak Ltd.

BofA Merrill Lynch Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking revenues.

## Other Important Disclosures

Officers of MLPF&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

**BofA Merrill Lynch Global Research policies relating to conflicts of interest are described at <http://www.ml.com/media/43347.pdf>.**

**"BofA Merrill Lynch" includes Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") and its affiliates. Investors should contact their BofA Merrill Lynch representative or Merrill Lynch Global Wealth Management financial advisor if they have questions concerning this report.**

**Information relating to Non-US affiliates of BofA Merrill Lynch and Distribution of Affiliate Research Reports:**

MLPF&S distributes, or may in the future distribute, research reports of the following non-US affiliates in the US (short name: legal name): Merrill Lynch (France); Merrill Lynch Capital Markets (France) SAS; Merrill Lynch (Frankfurt); Merrill Lynch International Bank Ltd., Frankfurt Branch; Merrill Lynch (South Africa); Merrill Lynch South Africa (Pty) Ltd.; Merrill Lynch (Milan); Merrill Lynch International Bank Limited; MLI (UK); Merrill Lynch International; Merrill Lynch (Australia); Merrill Lynch Equities (Australia) Limited; Merrill Lynch (Hong Kong); Merrill Lynch (Asia Pacific) Limited; Merrill Lynch (Singapore); Merrill Lynch (Singapore) Pte Ltd.; Merrill Lynch (Canada); Merrill Lynch Canada Inc; Merrill Lynch (Mexico); Merrill Lynch Mexico, SA de CV, Casa de Bolsa; Merrill Lynch (Argentina); Merrill Lynch Argentina SA; Merrill Lynch (Japan); Merrill Lynch Japan Securities Co., Ltd.; Merrill Lynch (Seoul); Merrill Lynch International Incorporated (Seoul Branch); Merrill Lynch (Taiwan); Merrill Lynch Securities (Taiwan) Ltd.; DSP Merrill Lynch (India); DSP Merrill Lynch Limited; PT Merrill Lynch (Indonesia); PT Merrill Lynch Indonesia; Merrill Lynch (Israel); Merrill Lynch Israel Limited; Merrill Lynch (Russia); Merrill Lynch CIS Limited, Moscow; Merrill Lynch (Turkey); Merrill Lynch Yatirim Bankasi A.S.; Merrill Lynch (Dubai); Merrill Lynch International, Dubai Branch; MLPF&S (Zürich rep. office); MLPF&S Incorporated Zürich representative office; Merrill Lynch (Spain); Merrill Lynch Capital Markets Espana, S.A.S.V.; Merrill Lynch (Brazil); Bank of America Merrill Lynch Banco Múltiplo S.A.

This research report has been approved for publication and is distributed in the United Kingdom to professional clients and eligible counterparties (as each is defined in the rules of the Financial Services Authority) by Merrill Lynch International and Banc of America Securities Limited (BASL), which are authorized and regulated by the Financial Services Authority and has been approved for publication and is distributed in the United Kingdom to retail clients (as defined in the rules of the Financial Services Authority) by Merrill Lynch International Bank Limited, London Branch, which is authorized by the Central Bank of Ireland and is subject to limited regulation by the Financial Services Authority – details about the extent of its regulation by the Financial Services Authority are available from it on request; has been considered and distributed in Japan by Merrill Lynch Japan Securities Co., Ltd., a registered securities dealer under the Financial Instruments and Exchange Act in Japan; is distributed in Hong Kong by Merrill Lynch (Asia Pacific) Limited, which is regulated by the Hong Kong SFC and the Hong Kong Monetary Authority; is issued and distributed in Taiwan by Merrill Lynch Securities (Taiwan) Ltd.; is issued and distributed in India by DSP Merrill Lynch Limited; and is issued and distributed in Singapore by Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd. (Company Registration No.'s F 06872E and 198602883D respectively) and Bank of America Singapore Limited (Merchant Bank). Merrill Lynch International Bank Limited (Merchant Bank) and Merrill Lynch (Singapore) Pte Ltd. are regulated by the Monetary Authority of Singapore. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 provides this report in Australia in accordance with section 911B of the Corporations Act 2001 and neither it nor any of its affiliates involved in preparing this research report is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this report in Brazil. Merrill Lynch (Dubai) is authorized and regulated by the Dubai Financial Services Authority (DFSA). Research reports prepared and issued by Merrill Lynch (Dubai) are prepared and issued in accordance with the requirements of the DFSA conduct of business rules.

Merrill Lynch (Frankfurt) distributes this report in Germany. Merrill Lynch (Frankfurt) is regulated by BaFin.

This research report has been prepared and issued by MLPF&S and/or one or more of its non-US affiliates. MLPF&S is the distributor of this research report in the US and accepts full responsibility for research reports of its non-US affiliates distributed to MLPF&S clients in the US. Any US person receiving this research report and wishing to effect any transaction in any security discussed in the report should do so through MLPF&S and not such foreign affiliates.

### **General Investment Related Disclosures:**

This research report provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this report.

Securities and other financial instruments discussed in this report, or recommended, offered or sold by Merrill Lynch, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Merrill Lynch is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned in this report. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

UK Readers: The protections provided by the U.K. regulatory regime, including the Financial Services Scheme, do not apply in general to business coordinated by BofA Merrill Lynch entities located outside of the United Kingdom. BofA Merrill Lynch Global Research policies relating to conflicts of interest are described at <http://www.ml.com/media/43347.pdf>.

Officers of MLPF&S or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments.

MLPF&S or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. MLPF&S or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

30 January 2012

BofA Merrill Lynch, through business units other than BofA Merrill Lynch Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented in this report. Such ideas or recommendations reflect the different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Merrill Lynch is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this report.

In the event that the recipient received this report pursuant to a contract between the recipient and MLPF&S for the provision of research services for a separate fee, and in connection therewith MLPF&S may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom MLPF&S has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by MLPF&S). MLPF&S is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities mentioned in this report.

**Copyright and General Information regarding Research Reports:**

Copyright 2012 Merrill Lynch, Pierce, Fenner & Smith Incorporated. All rights reserved. iQmethod, iQmethod 2.0, iQprofile, iQtoolkit, iQworks are service marks of Merrill Lynch & Co., Inc. iQanalytics®, iQcustom®, iQdatabase® are registered service marks of Merrill Lynch & Co., Inc. This research report is prepared for the use of BofA Merrill Lynch clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Merrill Lynch. BofA Merrill Lynch Global Research reports are distributed simultaneously to internal and client websites and other portals by BofA Merrill Lynch and are not publicly-available materials. Any unauthorized use or disclosure is prohibited. Receipt and review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets) without first obtaining expressed permission from an authorized officer of BofA Merrill Lynch.

Materials prepared by BofA Merrill Lynch Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Merrill Lynch, including investment banking personnel. BofA Merrill Lynch has established information barriers between BofA Merrill Lynch Global Research and certain business groups. As a result, BofA Merrill Lynch does not disclose certain client relationships with, or compensation received from, such companies in research reports. To the extent this report discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this report. BofA Merrill Lynch Global Research personnel's knowledge of legal proceedings in which any BofA Merrill Lynch entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving companies mentioned in this report is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of BofA Merrill Lynch in connection with the legal proceedings or matters relevant to such proceedings.

This report has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of MLPF&S, any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Merrill Lynch Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Merrill Lynch and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This report may contain links to third-party websites. BofA Merrill Lynch is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this report and is not incorporated by reference into this report. The inclusion of a link in this report does not imply any endorsement by or any affiliation with BofA Merrill Lynch. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Merrill Lynch is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Merrill Lynch policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports may contain discussions and/or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent research report relating to a company or issuer prior to making an investment decision.

In some cases, a company or issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such company or issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with MLPF&S or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Merrill Lynch nor any officer or employee of BofA Merrill Lynch accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents.